Floatz logo

Therapeutic Asset Ratings

4,361 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Letrozole
Estrogen-Receptor Positive Breast Cancer
National Cancer Institute (NCI)P3BB (66)
METHOTREXATE
T-Cell Adult Acute Lymphocytic Leukemia
National Cancer Institute (NCI)P3BB (66)
PREDNISONE TABLETS
High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement
National Cancer Institute (NCI)P3BB (66)
Solu-Cortef
B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)P3BB (66)
Solu-Cortef
T-Cell Childhood Acute Lymphocytic Leukemia
National Cancer Institute (NCI)P3BB (66)
Sorafenib
Cutaneous Melanoma
National Cancer Institute (NCI)P3BB (66)
TAMOXIFEN
Lobular Breast Carcinoma In Situ
National Cancer Institute (NCI)P3BB (66)
Tas-102
Carcinoma, Islet Cell
National Cancer Institute (NCI)P3BB (66)
VINBLASTINE
Hodgkin'S Lymphoma, Lymphocytic Depletion
National Cancer Institute (NCI)P3BB (66)
VINBLASTINE
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)P3BB (66)
VINBLASTINE
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
National Cancer Institute (NCI)P3BB (66)
VINBLASTINE
Nodular Sclerosis Classical Hodgkin Lymphoma
National Cancer Institute (NCI)P3BB (66)
VINCRISTINE SULFATE
T-Cell Adult Acute Lymphocytic Leukemia
National Cancer Institute (NCI)P3BB (66)
Atezolizumab
Urinary Bladder Cancer
National Cancer Institute (NCI)P2BB (66)
Bendamustine
High Grade B-Cell Lymphoma
National Cancer Institute (NCI)P2BB (66)
Binimetinib
Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)P2BB (66)
Bms-907351
Papillary Renal Cell Carcinoma
National Cancer Institute (NCI)P2BB (66)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Renal Pelvis/Ureter Urothelial Carcinoma
National Cancer Institute (NCI)P2BB (66)
Epirubicin
Metastatic Head and Neck Carcinoma
National Cancer Institute (NCI)P2BB (66)
Irinotecan
Myelodysplastic Syndrome With Excess Blasts
National Cancer Institute (NCI)P2BB (66)
Irinotecan
Ovarian Carcinosarcoma
National Cancer Institute (NCI)P2BB (66)
Olaparib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2BB (66)
Olaparib
Unresectable Pancreatic Carcinoma
National Cancer Institute (NCI)P2BB (66)
PANITUMUMAB
Breast Cancer
National Cancer Institute (NCI)P2BB (66)
Pembrolizumab
Head And Neck Carcinoma
National Cancer Institute (NCI)P2BB (66)
Showing 326 to 350 of 4,361 assets
PreviousPage 14 of 175Next